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Abstract
The HSP90 molecular chaperone plays a key role in the maturation, stability and activation of its 
clients, including many oncogenic proteins. Kinases are a substantial and important subset of 
clients requiring the key cochaperone CDC37. We sought an improved understanding of protein 
kinase chaperoning by CDC37 in cancer cells. CDC37 overexpression in human colon cancer cells 
increased CDK4 protein levels, which was negated upon CDC37 knockdown. Overexpressing 
CDC37 increased CDK4 protein half-life and enhanced binding of HSP90 to CDK4, consistent 
with CDC37 promoting kinase loading onto chaperone complexes. Against expectation, 
expression of C-terminus truncated CDC37 (ΔC-CDC37) that lacks HSP90 binding capacity did 
not affect kinase client expression or activity; moreover, as with wildtype CDC37 overexpression, 
it augmented CDK4-HSP90 complex formation. However, although truncation blocked binding to 
HSP90 in cells, ΔC-CDC37 also showed diminished client protein binding and was relatively 
unstable. CDC37 mutants with single and double point mutations at residues M164 and L205 
showed greatly reduced binding to HSP90, but retained association with client kinases. 
Surprisingly, these mutants phenocopied wildtype CDC37 overexpression by increasing CDK4-
HSP90 association and CDK4 protein levels in cells. Furthermore, expression of the mutants was 
sufficient to protect kinase clients CDK4, CDK6, CRAF and ERBB2 from depletion induced by 
silencing endogenous CDC37, indicating that CDC37’s client stabilising function cannot be 
inactivated by substantially reducing its direct interaction with HSP90. However, CDC37 could 
not compensate for loss of HSP90 function, showing that CDC37 and HSP90 have their own 
distinct and non-redundant roles in maintaining kinase clients. Our data substantiate the important 
function of CDC37 in chaperoning protein kinases. Furthermore, we demonstrate that CDC37 can 
stabilise kinase clients by a mechanism that is not dependent on a substantial direct interaction 
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between CDC37 and HSP90, but nevertheless requires HSP90 activity. These results have 
significant implications for therapeutic targeting of CDC37.
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Introduction
Client protein chaperoning by HSP90 requires a specialised cohort of cochaperones (1). 
Through the formation of transient complexes, these cochaperones participate in progression 
of the ATP-dependent chaperone cycle and maturation of client proteins to enable their 
eventual functional activities (2). CDC37 acts predominantly as a kinase-specific 
cochaperone. The yeast CDC37 homologue is essential for viability (3) and is estimated to 
regulate three quarters of the kinome (4). Similarly in mammalian cells, CDC37 interacts 
with a large proportion of kinases (5) and in concert with HSP90 directs the maturation of 
numerous oncogenic clients (6-12). Although the precise mechanisms by which CDC37 
facilitates the actions of HSP90 are not fully understood, it has been proposed that 
association of CDC37 with the N-terminus of HSP90 blocks its ATPase activity and helps 
kinase client loading before progression of the chaperone cycle (2;13;14).
CDC37 may also have the capacity to promote maturation of kinase clients independent 
from HSP90 (15;16). In Saccharomyces cerevisiae, the kinase-binding domain of Cdc37 
alone stabilised v-Src to some degree, indicating that it may function without direct HSP90 
interaction, albeit less efficiently (17). Similar truncated Cdc37 mutants were also sufficient 
to maintain the viability of Schizosaccharomyces pombe (18). The mechanism of this 
seemingly HSP90-independent activity is unknown and it is uncertain whether it is 
conserved in human CDC37. Against this notion is that C-terminally truncated mammalian 
CDC37 mutants deficient in binding to HSP90 were reported to reduce client activity (7;19) 
and decreased the expression of CRAF and CDK4 in normal prostate cells (20).
CDC37’s ability to regulate the chaperoning of several clients that promote cell cycle 
progression and survival suggests that it may be particularly important in cancer cells 
(21;22). In support of this, transgenic mice overexpressing CDC37 show an increased 
incidence of tumours (23;24). Furthermore, CDC37 may contribute towards the initiation of 
prostate cancer (24). We have previously shown that CDC37 knockdown causes depletion of 
kinase client proteins as well as growth inhibition in several cancer cell lines (25). Similarly, 
CDC37 silencing in prostate cancer cells reduced signaling through clients and induced 
growth arrest (26). Therefore, targeting CDC37 could represent a strategy for disrupting 
multiple kinase-dependent oncogenic signaling pathways that sustain malignancy (27;28).
Here we set out to understand further the functional role of CDC37 in human cancer cells. 
Complementing our previous knockdown approach (25), CDC37 overexpression was used 
to explore the extent to which selected protein kinase clients were dependent on CDC37 
levels for their chaperoning. Furthermore, by investigating the effects of CDC37 mutants 
that disrupt the interaction with HSP90, we demonstrate that CDK4 protein stability is 
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particularly dependent on the level of CDC37 but that substantial direct interaction of 
CDC37 with HSP90 is not required for efficient chaperoning of kinase clients. These results 
help to distinguish between the functions of CDC37 and HSP90, and have significant 
mechanistic and therapeutic implications.
Results
CDC37 overexpression increases cellular levels of client CDK4
To complement our previous CDC37 knockdown studies in HCT116 and HT29 colon 
cancer cells (25), we generated isogenic cell lines stably overexpressing CDC37 (Figure 1a). 
Two clones were chosen from each cell line, which expressed at least 8-fold (by 
densitometry of western blots; Supplementary Figure S1) more CDC37 compared to 
parental and empty vector-transfected cells (Figure 1a). The exogenous CDC37 was 
phosphorylated at Ser13 (Figure 1a, quantified in Supplementary Figure S2) and therefore 
activated (29). Although our siRNA silencing studies showed that CDC37 is required to 
maintain expression of these kinase clients (25), CDC37 overexpression did not affect 
cellular CRAF, AKT or phosphorylated AKT protein levels (Figure 1b, quantified in Figure 
1c). However, significant elevation of CDK4 protein was observed in all HCT116 and HT29 
clones that overexpressed CDC37 (Figure 1b, quantified in Figure 1c). In CDC37-
overexpressing clone C1, CDK4 levels were reduced to basal levels by silencing CDC37 
(siRNAs O3 and O4, Figure 1d). These data strongly suggested that constitutive CDC37 
levels are rate-limiting for the expression of CDK4, but not the other kinases studied.
Since HSP90 chaperoning aids the formation of active signaling-competent proteins (30), 
we next addressed whether increasing CDC37 levels promoted the signaling output from its 
clients. RAF kinase activity, measured by phosphorylated MEK1/2 and ERK1/2 levels, was 
unaltered in CDC37-overexpressing clones compared to empty vector controls (Figure 2a, 
quantified in Supplementary Figure S3). Despite elevated CDK4 expression, RB 
phosphorylation at S795 and S780 remained unchanged when CDC37 was overexpressed 
and Cyclin D1 expression was unaltered (Figure 2a). Since other factors may limit CDK4 
activity in intact cells, we performed a kinase assay with CDK4 immunoprecipitates to 
determine whether CDC37 overexpression increased intrinsic CDK4 activity. HCT116 and 
HT29 CDC37-overexpressing clones did not show different levels of RB phosphorylation 
activity compared to controls (Figure 2b). Therefore, although basal CDC37 levels were 
rate-limiting for CDK4 protein expression, they did not restrict the kinase activity of its 
clients.
CDC37 overexpression promotes CDK4 stabilisation
As elevated CDK4 levels in CDC37-overexpressing cells may be due to its increased 
stability, we assessed CDK4 protein half-life. CDC37-overexpressing clone C8 (HT29) 
showed a slower rate of CDK4 degradation following treatment with the protein synthesis 
inhibitor cycloheximide compared to the empty vector control (Figure 3a). Since CDK4 
stability is influenced by binding partners such as D Cyclins that have relatively short half-
lives (31), we also performed a pulse chase experiment to avoid potential artefacts resulting 
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from blocking protein synthesis. CDK4 half-lives were 3.3h in the empty vector clone, and 
9.7h in the CDC37-overexpressing clone (Figure 3b), an almost 3-fold increase.
To determine whether the dependence of CDK4 on CDC37 might be conserved with other 
close CDK family members, CDK6 was examined. CDK6 levels were unchanged in 
CDC37-overexpressing clones (Figure 3c). Consistent with this finding, CDK6 protein half-
life was similar in the empty vector control and CDC37-overexpressing clone (4.4h 
compared with 5.6h, respectively; Figure 3d). Therefore, the dependence of CDK4 on 
CDC37 was not shared by CDK6.
CDC37 overexpression promotes CDK4 binding to HSP90
We hypothesised that the increased CDK4 stability in CDC37-overexpressing cells was due 
to enhanced binding to HSP90. By immunoprecipitation we showed that more CDK4 was 
associated with HSP90 in CDC37-overexpressing HCT116 and HT29 cells than in the 
empty vector clones (Figure 4a, quantified in Supplementary Figure S4a). Less HSP90 was 
immunoprecipitated with CDK4 in HT29 cells than HCT116 cells, which is most likely due 
to lower expression of HSP90 and CDC37 in this cell line as shown in Supplementary 
Figure S4b. Although undetectable in HT29 cells, the level of Cyclin D1 associated with 
CDK4 was unaltered in HCT116 cells (Figure 4a).
Further analysis of protein complexes by gel filtration indicated that in control cells, CDK4 
peaked in three main forms: ~44kd, ~440kd and large complexes of >640kd (Figure 4b, 
top). Cyclin D1 segregated into complexes of <440kd, whereas HSP90 and CDC37 were 
most abundant in complexes of ~640kd and ~440kd, respectively. Interestingly, CDC37-
overexpressing cells exhibited a different distribution of CDK4 whereby the kinase was 
mostly present in higher molecular weight complexes containing HSP90 and CDC37, 
whereas the fractions in which HSP90, CDC37 and Cyclin D1 were detected were 
comparable with the vector control (Figure 4b, bottom). These data are consistent with 
CDC37 promoting CDK4 recruitment to large HSP90 chaperone complexes.
ΔC-CDC37 blocks HSP90 binding but enhances CDK4-HSP90 association
Since our findings so far were indicative that CDC37 supports client protein stabilisation by 
promoting binding to chaperone complexes, we next hypothesized that this required 
interaction between CDC37 and HSP90. To test this hypothesis we expressed CDC37 
protein truncated after aa173 (ΔC-CDC37), thereby lacking the HSP90-interacting C-
terminal domain (14) and blocking binding to HSP90 (17). ΔC-CDC37 was detected in 
transfected HCT116 and HT29 clones, although at a lower level than the endogenous 
CDC37, and was phosphorylated at Ser13 (Figure 5a). Against expectation, expression 
levels of client proteins CDK4, CRAF, BRAF and AKT were unchanged in cells that 
expressed ΔC-CDC37 (Figure 5a, quantified in Supplementary Figure S5). Downstream 
signaling output from CDK4 and RAF clients, as determined by phosphorylated ERK and 
RB respectively, revealed no changes, nor was there any alteration in AKT phosphorylation 
(Figure 5b). Since the presence of endogenous CDC37 could mask the ΔC-CDC37 
phenotype, we utilised siRNAs that silenced either the endogenous CDC37 only (O4: Figure 
5c) or both forms (O3: Figure 5c). Knockdown of endogenous CDC37 when ΔC-CDC37 
Smith et al. Page 4
Oncogene. Author manuscript; available in PMC 2015 July 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
was expressed resulted in clients CDK4 and CRAF being partially depleted to the same 
extent as observed by knockdown of both endogenous and ΔC-CDC37 (Figure 5c). 
Therefore, ΔC-CDC37 failed to act as a dominant negative with respect to client 
stabilisation.
Gel filtration separation of protein complexes in HCT116 and HT29 clones indicated that 
ΔC-CDC37 was present in much smaller molecular weight complexes than endogenous 
CDC37 (Figure 6a). HSP90 was not detected in the same fractions as ΔC-CDC37, consistent 
with ΔC-CDC37 being impaired in binding HSP90. In contrast, some CDK4 was found in 
the same fractions as ΔC-CDC37, suggesting that they could coexist in a complex (Figure 
6a). Interestingly, both ΔC-CDC37-expressing clones exhibited a shift of endogenous 
CDC37 and CDK4 to larger complexes, possibly indicating an increase in HSP90-
endogenous CDC37-client complexes (Figure 6a). Supporting this, increased binding of 
CDK4 to HSP90 was confirmed by immunoprecipitation of CDK4 from ΔC-CDC37-
expressing clones (Figure 6b, c, quantified in Supplementary Figure S6). In HCT116 cells 
the increased binding of CDK4 to HSP90 was more apparent in clone T11 than T9, 
consistent with higher expression of ΔC-CDC37 in clone T11 than T9 (Figure 5a, b). 
Therefore, contrary to our original hypothesis that CDC37-HSP90 binding deficiency would 
compromise the chaperoning of clients, the formation of CDK4-HSP90 complexes was 
actually enhanced.
ΔC-CDC37 shows decreased binding to clients and reduced stability
As CDC37 forms functional dimers (13;14;32), we next questioned whether ΔC-CDC37 
heterodimerised with endogenous CDC37 in HCT116 cells, as this could afford an increased 
functionality to ΔC-CDC37. Following dual expression of HA- or FLAG-tagged CDC37 
and ΔC-CDC37, we looked for wildtype and truncated CDC37 in FLAG 
immunoprecipitates (Supplementary Figure S7a). No HA-ΔC-CDC37 was detected in a 
FLAG-CDC37 pulldown, nor was HA-CDC37 observed in a FLAG-ΔC-CDC37 pulldown, 
suggesting that ΔC-CDC37 does not dimerise with wildtype CDC37. Thus 
heterodimerisation is unlikely to be a complicating factor in assessing the ΔC-CDC37 
phenotype.
Next, to determine whether the C-terminal deletion affected client binding, we expressed 
FLAG-tagged CDC37 or ΔC-CDC37 and analysed FLAG immunoprecipitates. Firstly, we 
confirmed that ΔC-CDC37 did not associate with HSP90; however, increased binding to 
HSC70 (HSP70) was seen (Supplementary Figure S7b). Interestingly, much less CDK4 or 
CRAF were bound to FLAG-ΔC-CDC37 compared to FLAG-CDC37 (Supplementary 
Figure S7b). This finding may indicate that in the absence of a direct interaction with 
HSP90, CDC37 has a lower affinity for client proteins or that the C-terminus of CDC37 is 
involved in binding clients, as suggested by others (33).
Since removal of the C-terminus may influence the overall structure and/or stability of 
CDC37, we determined the half-life of ΔC-CDC37 using a post-cycloheximide time course. 
As shown in Supplementary Figure S7c, ΔC-CDC37 degraded rapidly in HCT116 and HT29 
cells and has a much shorter half-life than endogenous CDC37, consistent with lower 
expression levels of the mutant form (Figure 5a). Together with the decreased binding to 
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kinase clients, the instability of the C-terminal deletion mutant likely had detrimental effects 
in addition to the intended loss of HSP90 binding. Thus we subsequently sought additional, 
more specific mutants to model inhibition of CDC37-HSP90 association.
CDC37 point mutations reduce binding to HSP90
Appropriate mutations were chosen based on the structure of CDC37 in complex with 
HSP90. The electron microscopy-derived model of a CDC37-CDK4-HSP90 complex 
(Figure 7a) and CDC37-HSP90 X-ray crystal structure (Figure 7b) indicate how the N-
terminal domains of HSP90 dimers interact with the CDC37 C-terminal domain. Several 
critical residues are involved in a hydrophobic interaction: we chose to modify residues 
M164 and L205, which from a model of the CDC37-HSP90 interface (Figure 7c) were 
predicted to disrupt the protein-protein interaction without compromising the rest of the 
protein. Both residues were substituted with either alanine as a small residue, or arginine to 
introduce a positive charge, and the corresponding single and double mutants generated.
FLAG-tagged wildtype or mutant CDC37 constructs were transfected into HCT116 and 
HT29 colon cancer cells, giving higher expression than the endogenous CDC37 (HCT116 
shown in Figure 7d and 12-fold overexpression estimated for mutant M164A in 
Supplementary Figure S8). To determine how the mutations affected chaperone complexes, 
FLAG immunoprecipitates were analysed. As predicted, in both HCT116 and HT29 cells, 
less HSP90 associated with all the mutants compared to wildtype CDC37 (Figure 7e). Of 
note, quantitation indicated that M164R/L205R was partially effective at blocking HSP90 
association whilst mutants M164A and L205A disrupted the interaction by 94% and 90%, 
respectively (Figure 7f). As further confirmation, ITC measurements with purified 
recombinant proteins gave Kd values of 2.26μM and 7.19μM for the binding to HSP90β of 
FLAG-tagged wildtype and M164A, respectively, and the FLAG-CDC37 M164R/L205R 
double mutant showed no detectable binding. The differences in the binding observed for 
purified recombinant protein and intact cell settings could be due to effects of additional 
proteins in cellular chaperone complexes. However, the key point is that the CDC37 mutants 
were shown to exhibit reduced HSP90 binding in cells, which was substantial and almost 
complete in some cases.
As expected and in contrast to ΔC-CDC37 (Supplementary S7b), client proteins CDK4 and 
CDK6 associated with all of the CDC37 point mutants to the same extent as wildtype 
CDC37 in cells (Figure 7e). Interestingly, CDC37 M164A/L205A and all the arginine-
substituted mutants showed greater binding to CRAF, particularly in HT29 cells (Figure 7e) 
but consistent with basal CDC37 activity not being rate limiting for CRAF in these cells 
lines (Figure 1b, c) this did not affect CRAF expression levels.
CDC37 point mutants retain the ability to promote chaperoning of CDK4
To determine whether the HSP90 binding-impaired CDC37 mutants compromised client 
protein stability, we analysed the expression level of several clients. Firstly, we confirmed 
that all CDC37 mutants were phosphorylated (Figure 8a). Next, we found no change in 
ERBB2, CRAF or AKT expression following overexpression of the CDC37 mutants, as also 
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observed with wildtype overexpression (Figure 8a, CRAF quantified in Supplementary 
Figure S9).
For subsequent studies we primarily focussed on CDC37 point mutants M164A, L205A and 
M164R/L205R that most effectively blocked binding to HSP90 (in cells by 
immunoprecipitation or with recombinant proteins by ITC). These CDC37 mutants did not 
affect the signalling output of kinase clients, as determined by phosphorylation of AKT and 
ERK1/2 in HCT116 (Figure 8b).
In agreement with our earlier findings (Figure 1a), CDK4 expression was elevated in cells 
overexpressing FLAG-tagged wildtype CDC37 (Figure 8a, quantified in Supplementary 
Figure S9). Surprisingly, instead of compromising the chaperoning of this client as 
predicted, CDK4 levels were elevated similarly to wildtype when any of the mutants were 
expressed (Figure 8a, quantified in Supplementary Figure S9). Furthermore, CDK4 
immunoprecipitates from all mutant CDC37-expressing cells showed increased CDK4-
HSP90 association similar to that seen with wildtype FLAG-CDC37 overexpression (Figure 
8c, quantified in Supplementary Figure S10). Thus expressing HSP90 binding-impaired 
CDC37 point mutants unexpectedly phenocopied wildtype CDC37 overexpression.
A possible explanation for the ability of the CDC37 point mutants to promote the 
chaperoning of CDK4, despite substantially compromised interaction with HSP90, could be 
the formation of mutant-wildtype CDC37 dimers that may account for the small amount of 
HSP90 detected in immunoprecipitates of the selected CDC37 mutants (Figure 7e). 
However, specific silencing of endogenous CDC37 expression using 3′ UTR-targeted 
siRNA before immunoprecipitation of CDC37 M164A or L205A failed to reduce HSP90 
binding further when compared with FLAG-CDC37 (Figure 8d). Furthermore, CDK4 
association with the CDC37 mutants was also unaffected by endogenous CDC37 
knockdown. Thus the unexpected retention of chaperoning activity by the CDC37 point 
mutants cannot be attributed to heterodimerisation with endogenous CDC37.
CDC37 point mutants can replace the chaperoning role of endogenous CDC37 but not 
HSP90
Our findings so far indicated that the CDC37 point mutants that block HSP90 interaction act 
similarly to wildtype CDC37 in promoting the chaperoning of CDK4. We rationalised that 
the mutants could potentially replace the chaperone function of endogenous CDC37. To test 
this, we silenced endogenous CDC37 and examined the effect on kinase client proteins. As 
shown in Figure 9a, CDC37 knockdown in parental HCT116 cells caused the expected 
depletion of CDK4, CDK6, CRAF and ERBB2 (25). High-level expression of FLAG-
CDC37 rescued depletion of kinase proteins following exposure to siRNA that silenced 
wildtype CDC37 (Figure 9a, quantified in Supplementary Figure S11). Importantly, 
expression of CDC37 M164A or L205A mutants was also sufficient to protect HSP90/
CDC37 clients CDK4, CDK6, CRAF and ERBB2 from depletion by CDC37 knockdown 
(Figure 9a, quantified in Supplementary Figure S11). These results suggested that despite a 
severely restricted capacity to bind HSP90, the CDC37 point mutants were nevertheless still 
functional in maintaining client protein stability in cells.
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Assaying kinase activity following knockdown of endogenous CDC37 demonstrated that 
CDK4 function was not affected by expression of the point mutants, as also seen with 
wildtype CDC37 overexpression (Figure 9b). This is consistent with CDC37 primarily 
affecting the stability rather than the activity of CDK4.
The hypothesis that CDC37 may chaperone clients independently of HSP90 led us next to 
determine if the CDC37 mutants could compensate for loss of HSP90 activity. We found 
that partial knockdown of HSP90α and HSP90β resulted in a reduction of client proteins 
such as CDK4 and ERBB2 (Figure 9c). However, overexpression of wildtype CDC37 or 
mutants M164A or L205A did not lessen the extent of client protein depletion upon HSP90 
silencing. In addition, we found that CDC37 overexpression rescues the sensitisation to 
pharmacological HSP90 inhibitors that we previously observed (25) upon silencing of 
CDC37, and that overexpression of CDC37 mutants M164A, L205A or M164R/L205R has 
the same protective effect (Table 1). Moreover, overexpression of wildtype or mutant 
CDC37 did not result in cellular resistance to the HSP90 inhibitor 17-AAG compared to the 
parental cells. Together, these results demonstrate that CDC37 cannot substitute for HSP90 
in chaperoning kinase clients and both must play an important role, even though significant 
direct binding between the two is not required.
Discussion
To complement our previous siRNA silencing studies showing that several HSP90 clients 
were dependent on CDC37 in cancer cells (25), here we used an overexpression and 
mutation approach to further investigate the role of CDC37 in client stabilisation, as well as 
specifically exploring the importance of CDC37’s direct interaction with HSP90. We found 
that overexpressing wildtype CDC37 in human colon cancer cell lines HCT116 and HT29 
had no effect on the expression and signalling output of all but one of the representative 
CDC37 clients studied, the only exception being a clear increase in CDK4 protein levels. 
Our results are in contrast to those in normal prostate epithelia in which CDC37 
overexpression promoted the activity of clients (20). These differences may be rationalised 
by the elevation in CDC37 levels seen in several cancers (24;34;35), which could account 
for high CDC37 activity in the cancer cell lines we studied, so that increased expression had 
no further effect. Since the chaperoning of kinase clients is mediated by a multi-protein 
complex including HSP70, HSP90, HSP40, CDC37 and CK2 (36), other components could 
also become limiting when CDC37 is overexpressed.
We demonstrate that CDC37 has an important role in maintaining CDK4 stability in colon 
cancer cells and furthermore that binding of CDK4 to HSP90 is increased by CDC37 
overexpression, consistent with a model in which CDC37 promotes client association with 
the chaperone (6;13). It is uncertain why the basal expression levels of CDC37 were rate-
limiting for this client but not others; differences in the degree of dependence on CDC37 by 
particular client proteins were also shown in our CDC37 siRNA knockdown studies (25). 
The strong dependence of CDK4 on CDC37 is consistent with the close correlation between 
CDC37 and Cyclin D1 expression in highly proliferative tissues (6). We did not observe a 
concomitant increase in stability of a closely related CDK, CDK6, in CDC37-
overexpressing cells; this could be due in part to the stronger association of CDC37 with 
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CDK4 compared to CDK6 (6). Despite elevated CDK4 levels, neither its kinase activity nor 
active CDK4/Cyclin D complexes were increased in CDC37-overexpressing cells. CDC37 
and Cyclin D1 overexpression collaborate in tumourigenesis (23;34), which could suggest 
that in our models Cyclin D1 levels may become limiting for CDK4 kinase activity when 
overexpressing CDC37.
In addition to its cochaperone role, yeast Cdc37 was suggested to have its own chaperoning 
capacity separate from HSP90 (15). Evidence for such independent activity with human 
CDC37 was previously lacking. In yeast, Cdc37 exists predominantly free from HSP90 
complexes (18;37); thus the likelihood of Hsp90-independent functionality may be greater 
than for human CDC37 which binds HSP90 more tightly (13). Indeed, expression of an 
HSP90 binding-impaired C-terminally truncated CDC37 in non-immortalised human 
prostate cells blocked CDC37 activity leading to loss of kinase client proteins, growth arrest 
and apoptosis (20). The same CDC37 mutant also exhibited dominant negative effects on 
the client CRAF in insect cells (7), suggesting that direct interaction with HSP90 was 
essential for CDC37 function. To further investigate CDC37’s potential HSP90-independent 
activity in human tumour cells we expressed a similar C-terminal truncation mutant (17) in 
the HCT116 and HT29 colon cancer lines in which we had previously characterised the 
phenotypes of CDC37 knockdown (25) and overexpression (herein). Surprisingly, although 
we confirmed that truncation prevented HSP90 binding, ΔC-CDC37 expression did not alter 
the levels or activity of clients defined by RNAi to be CDC37-dependent (25) and therefore 
did not act as a dominant negative. On the contrary, an unexpected increase in CDK4-
HSP90 complexes and shift towards higher molecular weight HSP90 chaperone complexes 
suggested that ΔC-CDC37 could promote the recruitment of clients to HSP90. However, 
clients CDK4 and CRAF associated less with ΔC-CDC37 compared to wildtype CDC37, an 
observation also made for the interaction of a similar truncated CDC37 mutant with a 
mutant HCK client (38). Furthermore, in contrast to wildtype CDC37 overexpression, ΔC-
CDC37 did not cause an elevation in CDK4 levels, perhaps due to low expression of the 
mutant. We concluded that using a C-terminal deletion approach to block CDC37’s 
interaction with HSP90 is limited owing to the reduced interaction with kinase clients and 
instability of the mutant protein.
We reasoned that examining the importance of CDC37-HSP90 association required more 
subtle mutation analysis and so generated a series of CDC37 point mutants substituted at 
residues M164/L205 that are involved in HSP90 binding (14;39). Mutation of these two 
sites was previously found to be efficient at blocking the interaction between CDC37 and 
HSP90 in living cells (40). These studies and our own binding data provided validation for 
the use of the selected point mutants to inhibit CDC37-HSP90 association in our cancer cell 
models.
Surprisingly, instead of having a dominant negative effect on the chaperoning of CDC37 
clients, we found that M164 and L205 mutants, that showed substantially reduced binding to 
HSP90, were able to phenocopy wildtype CDC37 overexpression. In agreement with our 
findings, another CDC37 mutant deficient in HSP90 binding failed to perturb the activity of 
a mutant HCK client in human cells, and in fact modestly increased its kinase activity and 
augmented binding of the client to HSP90 (38). In our own studies, an increase in CDK4 
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expression and CDK4-HSP90 association, comparable to wildtype, was apparent when the 
CDC37 point mutants were expressed. Furthermore, the HSP90 binding-impaired mutants 
were able to substitute for endogenous CDC37 in maintaining the stabilisation of client 
proteins CDK4, CDK6, CRAF and ERBB2, again similar to overexpressed wildtype 
CDC37. These findings were indicative of substantial direct CDC37-HSP90 binding 
mediated by the C-terminus of CDC37 with N-terminus of HSP90 not being essential for 
CDC37 to chaperone kinase clients in cells.
Although CDC37 may possess activity when free from HSP90 complexes (15), we found 
evidence that CDC37 and HSP90 do not have completely redundant roles, since CDC37 
overexpression could not compensate for the effects of HSP90 knockdown or treatment with 
an HSP90 inhibitor. One possibility is that the two proteins have separate but sequential 
roles in kinase client maturation.
A current model for CDC37’s cochaperone role involves its interaction with the N-terminus 
of HSP90 transiently inhibiting the HSP90 ATPase cycle, thereby permitting the loading of 
client proteins (14, Figure 10; Model A). Our results indicate that, at least under conditions 
where direct CDC37-HSP90 binding is severely restricted, CDC37 can efficiently maintain 
the maturation of clients by promoting the association of kinase clients with HSP90 through 
an alternative mechanism (Figure 10; Model B). Since kinase clients may interact with 
HSP90 in a specific orientation, as suggested for CDK4 in which the two lobes of the kinase 
bind to separate domains of HSP90 allowing conformational changes to be relayed during 
the chaperone cycle (41), one speculative role for CDC37 could be to present clients in a 
conformation that is more amenable to HSP90 association. It is unclear whether CDC37 
possesses intrinsic chaperoning activity or acts more as a scaffold that protects clients from 
degradation prior to chaperoning by HSP90, which due to their inherent instability may be 
particularly important for immature protein kinases (42). Elucidation of the precise 
mechanism by which CDC37 and HSP90 are able to chaperone kinase clients is of 
considerable interest. This will best be addressed by extensive proteomic and structural 
biology studies.
The largely kinase-specific clientele of CDC37 presents an opportunity to target selectively 
an important oncogenic subset of HSP90 clients (21;28). So far, specific inhibitors of 
CDC37 have not been reported. Natural product inhibitors celastrol and withaferin A disrupt 
the interaction between HSP90 and CDC37 and show anticancer activity (43;44), although 
this has not been linked directly to CDC37 blockade, particularly in the case of celastrol, 
which elicits its growth inhibitory effect via multiple mechanisms (45). While our data 
support CDC37 as a potential cancer drug target, importantly, our results with M164/L205 
mutants indicate that substantially disrupting the CDC37-HSP90 protein interaction 
mediated by this C-terminal region of CDC37 is not sufficient to prevent the cochaperone 
from promoting HSP90-client association. This suggests that therapeutic alternatives to 
blocking CDC37-HSP90 association are needed. Possible strategies could involve targeting 
other CDC37 interactions, for example homodimerisation or client binding (46). CDC37’s 
N-terminal region is implicated in binding to kinases (47); however, other regions may also 
influence the interaction (33). Phosphorylation/dephosphorylation of CDC37 is another 
important regulatory process that could be targeted (48;49). Further research into these other 
Smith et al. Page 10
Oncogene. Author manuscript; available in PMC 2015 July 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
aspects of CDC37 regulation will be required to define druggable means for inhibiting 
CDC37, as well as to more completely understand the chaperone role of CDC37 in cancer 
and normal cells.
Materials and methods
Cell culture
HCT116 and HT29 human colon cancer cell lines were obtained from ATCC and cultured in 
DMEM (Sigma-Aldrich, Gillingham, UK) supplemented with 10% FCS (PAA Laboratories, 
UK), 2mM L-glutamine and non-essential amino acids (Invitrogen, Paisley, UK). Cells were 
maintained at 37°C, 5% CO2 in a humidified incubator.
Plasmid cloning and transfection
See supplementary information for primer and oligo sequences. CDC37 open reading frame 
was amplified by RT-PCR from human MCF-7 cDNA using primers P1/P2. The C-terminal 
truncation mutant was generated with primers P1/P3 which introduced a stop codon after 
aa173. Products were blunt cloned into pPCR-Script Amp (Stratagene, Agilent 
Technologies, Stockport, UK) or pCR4Blunt TOPO (Invitrogen) and fully sequenced. For 
point mutations the QuikChange Multi Site-directed mutagenesis kit (Stratagene) was used 
with primers P4-P7. CDC37 constructs were transferred to bicistronic eukaryotic expression 
vectors pEFIRES-P or pEFIRES-N (50) , N-terminal tags being added subsequently. 
Transfection of supercoiled plasmid DNA was performed with Lipofectamine 2000 
(Invitrogen). Stable transfectants were selected with 3μg/ml puromycin (Sigma-Aldrich) and 
1mg/ml G418 (Invitrogen; dual construct transfections only).
siRNA transfection
Transfection of 20nM CDC37 or control siRNAs was performed using Oligofectamine 
(Invitrogen) according to the manufacturer’s protocol. Hiperfect (Qiagen) reverse 
transfection protocol was used for 100nM HSP90α and HSP90β or corresponding inactive 
siRNAs. Sequences are detailed in supplementary information.
Western blotting and immunoprecipitation
As described previously (25). Blots shown are representative of at least 2 independent 
experiments. Antibodies and densitometry are detailed in supplementary information.
Gel filtration
Cell pellets were resuspended in filtered lysis buffer (50mM Tris pH 7.6, 150mM NaCl, 
0.5% NP40, 1mM DTT) with complete protease inhibitor cocktail (Roche, Switzerland) and 
incubated on ice for 30 min. Samples were centrifuged at 17,000 × g for 30 min at 4°C, 
soluble lysates removed and centrifuged at 17,000xg until completely clear. 3mg protein 
was run through a 25ml Superose12 gel filtration column using an AKTA Chromatography 
system (GE Pharmacia, Amersham, UK), collecting 0.5ml fractions.
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Pulse chase
As described previously (25).
Isothermal titration calorimetry and Kd determinations
Detailed in supplementary information.
Growth inhibition assay
Sulphorhodamine B assay was performed as previously (25).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Kinase client levels following CDC37 overexpression
(a) Western blot showing total CDC37 and phospho-S13-CDC37 expression in wildtype 
(WT), empty vector-transfected (V) or CDC37-overexpressing HCT116 (clones C1 and 
C10) and HT29 (clones C8 and C12) colon cancer cells. The level of total CDC37 
overexpression is quantified in Supplementary Figure S1 and phospho-S13-CDC37 is 
quantified in Supplementary Figure S2. (b) Expression of CDC37, CRAF, CDK4, total AKT 
and S473-phosphorylated AKT in wildtype (WT), empty vector-transfected (V) or CDC37-
overexpressing HCT116 (C1, C10) and HT29 (C8, C12) cells. (c) Client protein expression 
in wildtype (WT), empty vector-transfected (Vec) or CDC37-overexpressing HCT116 (C1, 
C10) and HT29 (C8, C12) cells quantified by densitomety from western blots. Represented 
as mean±SE ratios relative to the wildtype cells from at least 3 independent experiments. 
Statistical analysis was performed using one-way ANOVA by comparison with empty 
vector-transfected controls. ns p>0.05; * p<0.05; ** p<0.01. (d) Expression of CDK4 
following 5 days siRNA-mediated knockdown of CDC37 (O3 and O4) in empty vector (V) 
or CDC37-overexpressing (C1) HCT116 cells. Controls are non-transfected (NT), mock 
transfected (Mk) and inactive siRNA (IC3 and IC4).
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Figure 2. Kinase client signalling activity following CDC37 overexpression
(a) Western blot showing phosphorylated ERK1/2, ERK2, phosphorylated MEK1/2, 
MEK1/2, phosphorylated RB (S795 and 780) and CYCLIN D1 expression in wildtype 
(WT), empty vector-transfected (V) or CDC37-overexpressing HCT116 (C1, C10) and 
HT29 (C8, C12) cells. ERK1/2 phosphorylation is quantified by densitometry in 
Supplementary Figure S3. (b) CDK4 kinase assay in wildtype (WT), empty vector-
transfected (V) or CDC37-overexpressing HCT116 (C1, C10) and HT29 (C8, C12) cells. 
Following CDK4 immunoprecipitation, and incubation with recombinant RB, S795-
phosphorylated RB and hypophosphorylated RB were measured by western blotting.
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Figure 3. Kinase client protein stability in CDC37-overexpressing cells
(a) Time course of CDK4 expression in empty vector-transfected or CDC37-overexpressing 
(C8) HT29 colon cancer cells following exposure to 20μg/ml cycloheximide (CHX). Left: 
Western blot, right: Mean densitometry of percentage CDK4 (relative to 0h) normalised to 
GAPDH ±SE from 3 independent repeats. (b) Pulse chase with 2h exposure to 150μCi/
ml 35S labelled methionine/cysteine and CDK4 immunoprecipitation. CDC37-
overexpressing clone C8 was compared with HT29 empty vector-transfected cells. Total 
CDK4 levels in each immunoprecipitate were determined by western blotting (WB). Below: 
Mean densitometry of percentage labelled CDK4 remaining ±SE from 3 independent 
repeats. (c) Expression of CDK6 in wildtype (WT), empty vector-transfected (V) or CDC37-
overexpressing (C8 and C12) HT29 cells. (d) Pulse chase with 2h exposure to 150μCi/ml 
35S labelled methionine/cysteine and CDK6 immunoprecipitation. CDC37-overexpressing 
clone C8 was compared with HT29 empty vector-transfected cells. Total CDK6 levels in 
each immunoprecipitate were determined by western blotting (WB). Below: Mean 
densitometry of percentage labelled CDK6 remaining ±SE from 3 independent repeats.
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Figure 4. CDK4 protein complexes in CDC37-overexpressing cells
(a) Western blot for HSP90, CDC37, CYCLIN D1 and CDK4 in whole cell lysates or CDK4 
immunoprecipitates from empty vector-transfected (V) or CDC37-overexpressing HCT116 
(C1, C10) and HT29 (C8, C12) colon cancer cells. The levels of HSP90 
coimmunoprecipitated with CDK4 in HCT116 cells are quantified by densitometry in 
Supplementary Figure S4a. (b) Western blot analysis of whole cell lysates (L) and fractions 
following Superose12 gel filtration separation of complexes. Approximate molecular 
weights are shown. CDC37-overexpressing clone C8 (HT29) is compared with HT29 empty 
vector-transfected clone.
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Figure 5. Kinase client expression and signalling activity in cells expressing ΔC-CDC37
(a) Western blot showing kinase clients and phospho-S13-CDC37 expression in wildtype 
(WT), empty vector-transfected (V) or ΔC-CDC37-expressing HCT116 (T9, T11) and HT29 
(T12, T32) colon cancer cells. Client protein expression is quantified by densitometry in 
Supplementary Figure S5. (b) Kinase client signalling output as measured by western blot 
analysis of phosphorylated RB (S780 and S795), phosphorylated ERK1/2 and S473-
phosphorylated AKT in wildtype (WT), empty vector-transfected (V) or ΔC-CDC37-
expressing HCT116 (T9, T11) and HT29 (T12, T32) colon cancer cells. (c) Client protein 
expression following 5 days knockdown of endogenous CDC37 (O3 and O4) in ΔC-CDC37-
expressing HT29 clone T32. Controls are no transfection (NT), mock transfection (Mk) and 
inactive siRNA (IC3 and IC4).
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Figure 6. Kinase client chaperone complexes in cells expressing ΔC-CDC37
(a) Western blot analysis of whole cell lysates and fractions following gel filtration 
separation of complexes using a Superose12 column. Parental HCT116 and HT29 cells are 
compared with ΔC-CDC37-expressing clones T11 and T12, respectively. (b) & (c) 
Immunoprecipitates of CDK4 and CDC37 from empty vector-transfected (V) or ΔC-
CDC37-expressing clones (b) HCT116 (T9, T11), and (c) HT29 (T12, T32). The levels of 
HSP90 co-immunoprecipitated with CDK4 in all HCT116 and HT29 clones are quantified 
by densitometry in Supplementary Figure S6.
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Figure 7. CDC37 point mutations reduce binding to HSP90
Cartoons showing interactions between HSP90 and CDC37: (a) The EM structure of the 
HSP90-CDC37-CDK4 complex. CDC37 (gold) interacts with the HSP90 N-terminal 
domains (blue). CDK4 (magenta) interacts with and the middle-domain (green) and C-
terminal domain (red) of HSP90. (b) The N-terminal domain of yeast HSP90 bound to the 
C-terminal domain of CDC37. (c) CDC37 (yellow) residues, M164 and L205 (shown in 
cyan), packing against the yeast HSP90 N-terminal domain (green). While mutation of 
M164 to alanine can be accommodated the mutation of L205 to the bulkier arginine cannot 
be easily accommodated. (d) Overexpression of FLAG-CDC37 (F) or 6 different FLAG-
CDC37 point mutants in HCT116 cells in comparison with the parental cells (P). The level 
of expression of CDC37 mutant 1 (M164A) is estimated by densitometry in Supplementary 
Figure S8. (e) Inputs and FLAG immunoprecipitates from HCT116 and HT29 cells 
overexpressing FLAG-CDC37 (F) or 6 different FLAG-CDC37 point mutants in 
comparison with parental cells (P). (f) Quantitation by densitometry of FLAG-CDC37 
mutants binding to HSP90 relative to FLAG-CDC37. CDC37 mutants are numbered as 
follows 1-M164A; 2-L205A; 3-M164A/L205A; 4-M164R; 5-L205R; 6-M164R/L205R.
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Figure 8. Kinase client expression, signaling activity and protein complexes following expression 
of CDC37 mutants
(a) Kinase client and S13-phosphorylated-CDC37 expression in HCT116 and HT29 cells. 
Overexpression of FLAG-CDC37 (F) or 6 different FLAG-CDC37 point mutants is 
compared with parental cells (P). Expression of clients CRAF and CDK4 in all cell lines is 
quantified by densitometry in Supplementary Figure S9. (b) S473-phosphorylated AKT and 
phosphorylated ERK1/2 expression in parental (P), FLAG-CDC37-overexpressing (F) or 3 
different FLAG-CDC37 point mutant-overexpressing HCT116 cell clones. (c) Inputs and 
CDK4 immunoprecipitates from parental (P), FLAG-CDC37-overexpressing (F) or 6 
different FLAG-CDC37 point mutant-overexpressing HCT116 cells. The levels of HSP90 
coimmunoprecipitated with CDK4 are quantified by densitometry in Supplementary Figure 
S10. (d) Inputs and FLAG immunoprecipitates from parental (P), FLAG-CDC37-
overexpressing (F) or 2 different FLAG-CDC37 point mutant-overexpressing HCT116 cell 
lines after 5 days transfection of Allstars negative control or CDC37 siRNA. CDC37 
mutants are numbered as follows 1-M164A; 2-L205A; 3-M164A/L205A; 4-M164R; 5-
L205R; 6-M164R/L205R.
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Figure 9. Rescue of wildtype CDC37 but not HSP90 function with CDC37 mutants
(a) Expression of kinase clients after knockdown with CDC37 siRNA or Allstars negative 
control siRNA for 4 or 5 days, comparing parental (P), FLAG-CDC37-overexpressing (F) 
and 2 different FLAG-CDC37 point mutant-overexpressing HCT116 cell lines. The rescue 
of CDK4, ERBB2 and CRAF client expression is quantified by densitometry in 
Supplementary Figure S11. (b) CDK4 kinase assay following 5 days transfection with 
Allstars negative control siRNA or CDC37 siRNA in parental (P), FLAG-CDC37-
overexpressing (F) or 3 different FLAG-CDC37 point mutant-overexpressing HCT116 cell 
lines. Following CDK4 immunoprecipitation, and incubation with recombinant RB, S795-
phosphorylated RB and hypophosphorylated RB were measured by western blotting. A 
control * without CDK4 IP is included. (c) Kinase client expression after transfection of 
HSP90α and HSP90β or inactive siRNA in parental (P), FLAG-CDC37-overexpressing (F) 
or 2 different FLAG-CDC37 mutant-overexpressing HCT116 cell lines. CDC37 mutants are 
numbered as follows 1-M164A; 2-L205A; 6-M164R/L205R.
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Figure 10. Models for the mechanism of action of CDC37 in the chaperoning of kinase clients
Two proposed models for the role of CDC37 in the chaperoning of kinase client proteins. 
Model A involves CDC37 directly binding to HSP90 thereby bringing kinase clients to the 
chaperone complex whereas Model B involves CDC37 altering kinases to promote their 
interaction with the chaperone complex as detailed in the numbered steps below. (1) CDC37 
is activated by phosphorylation on Ser13 by CK2 and interacts with unstable protein kinase 
clients. According to Model A, (2a) CDC37 directly brings kinase clients to HSP90 
chaperone complexes. (3a) CDC37 interacts with the N-terminus of HSP90 allowing the two 
lobes of the kinase client to interact in the correct conformation with HSP90 and (4) 
progression of the ATPase-dependent HSP90 chaperone cycle resulting in the formation of 
stable kinases competent for activity. In the alternative mechanism (Model B), (2b) the 
conformation of kinase clients bound to CDC37 is altered in such a way that may allow the 
two lobes of the kinase to be more amenable for interaction with HSP90. This could involve 
other components of the HSP90 chaperone system. (3b) The re-orientation of the kinase 
structure may allow the kinase to be released from CDC37 and bind to HSP90. This may or 
may not involve support from other proteins.
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Table 1
17-AAG GI50 (nM) in HCT116 cell lines with knockdown of endogenous CDC37 or 
control siRNA
Cell line Allstars siRNA CDC37 siRNA
Parental 49.7 ±2 *
 21.7 ±5
CDC37 46.3 ±2 39.0 ±12
CDC37 M164A 47.7 ±3 36.0 ±3
CDC37 L205A 54.0 ±8 49.7 ±20
CDC37 M164R/L205R 51.7 ±4 45.3 ±8
*p<0.05 comparing GI50 with CDC37 to Allstars siRNA
Mean ±SE from 3 independent experiments
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